15
2021-04
Suzhou, Apr.15, 2021--Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has received approval from the National Medical Products Administration to begin clinical trials for GT20029 (gel/tincture) for the treatment of acne and androgenetic alopecia.
12
2021-04
Suzhou, Apr.12, 2021--Kintor Pharmaceutical Limited (stock code 9939.HK, “Kintor Pharmaceutical” or the “Company”), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced a strategic partnership with Hainan Visum Pharmaceutical Limited (“Visum”) to expand proxalutamide manufacturing.
09
2021-04
Kintor Announces Presentation of Preclinical Data at AACR 2021
Suzhou, Apr.9, 2021--Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing small molecule and biological therapeutics, today announced two poster presentations of preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021, including proxalutamide(GT0918) to treat COVID-19 and a c-Myc inhibitor to treat blood cancer.
26
2021-03
Kintor Announces 2020 Business Progress and Annual Results
Suzhou, Mar.26, 2021--Kintor Pharmaceutical Limited (stock code 9939.HK, “Kintor Pharmaceutical” or the “Company”), a clinical-stage biotechnology company developing small molecule and biological therapeutics, recently announced its business highlights and financial results for the year ended December 31, 2020.
11
2021-03
SUZHOU, China, Mar 11, 2021--Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalutamide relative to standard of care as assessed by the COVID-19 ordinal scale. In the clinical trial, Proxalutamide met the primary endpoint at day 14, demonstrating a reduction of 4.01 in WHO COVID-19 ordinal scale from a baseline of 5.663 to 1.653 in the Proxalutamide arm versus a reduction of 0.25 from a baseline of 5.618 to 5.368 in the control arm with a p value <0.0001. Proxalutamide also demonstrated a reduction in mortality risk by 92% (3.7% vs 47.6%) and shortened median hospital length stayby 9 days (median hospital stay of 5 days vs 14 days).
05
2021-03
Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients Approved by FDA
Suzhou, Mar.5, 2021--Kintor Pharmaceutical Limited is pleased to announce that the Investigational New Drug (IND) application of the phase III clinical trial of Proxalutamide’s treatment of male COVID-19 outpatients has been approved by the United States Food and Drug Administration (FDA).
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn